cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Sage Therapeutics Inc
17 own
16 watching
Current Price
$22.65
$0.64
(2.91%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,164.1M
52-Week High
52-Week High
59.99000
52-Week Low
52-Week Low
16.51500
Average Volume
Average Volume
0.74M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
4.1438
iconMarket Capitalization1,164.1M
icon52-Week High59.99000
icon52-Week Low16.51500
iconAverage Volume0.74M
iconDividend Yield--
iconP/E Ratio4.1438
What does the Sage Therapeutics Inc do?
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The company's product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinson's diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Sage Therapeutics Inc make?
News & Events about Sage Therapeutics Inc.
Pharmaceutical Business Review
1 year ago
SAGE-718 is a first-in-class NMDA receptor positive allosteric modulator (PAM) as well as lead neuropsychiatric drug candidate. It is in development as a potential oral therapy for cognitive The post EMA grants ODD to Sage Therapeutics SAGE-718 to treat Huntingtons disease appeared first on ...
Business Wire
1 year ago
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an...
Globe Newswire
1 year ago
Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD)Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen ...
Business Wire
1 year ago
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that Chief Executive Officer, Barry Greene, will discuss the Companys progress in developing a leading brain health pipeline at the 41st Annual J.P. Morgan...
Frequently Asked Questions
Frequently Asked Questions
What is Sage Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Sage Therapeutics Inc shares?
plus_minus_icon
How can I buy Sage Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Sage Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Sage Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Sage Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Sage Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Sage Therapeutics Inc?
plus_minus_icon
What percentage is Sage Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Sage Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$22.65
$0.64
(2.91%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00